Immunic (NASDAQ:IMUX) Cut to Sell at StockNews.com

StockNews.com downgraded shares of Immunic (NASDAQ:IMUX) from a hold rating to a sell rating in a research note published on Monday.

Several other research analysts also recently weighed in on the company. HC Wainwright started coverage on Immunic in a research note on Monday, November 25th. They set a “buy” rating and a $10.00 target price on the stock. D. Boral Capital reissued a “buy” rating and issued a $17.00 price target on shares of Immunic in a report on Tuesday, January 7th. One research analyst has rated the stock with a sell rating, six have issued a buy rating and two have assigned a strong buy rating to the company. According to data from MarketBeat, the stock currently has an average rating of “Buy” and an average price target of $12.67.

Immunic Trading Down 1.3 %

NASDAQ IMUX opened at $0.94 on Monday. The firm’s fifty day simple moving average is $1.05 and its two-hundred day simple moving average is $1.27. The firm has a market capitalization of $84.50 million, a P/E ratio of -0.76 and a beta of 1.87. Immunic has a 12-month low of $0.92 and a 12-month high of $2.11.

Institutional Inflows and Outflows

A number of hedge funds have recently modified their holdings of IMUX. Jane Street Group LLC lifted its holdings in shares of Immunic by 121.4% during the third quarter. Jane Street Group LLC now owns 70,299 shares of the company’s stock worth $116,000 after purchasing an additional 38,553 shares during the period. HB Wealth Management LLC acquired a new stake in Immunic during the 4th quarter valued at approximately $81,000. State Street Corp lifted its stake in Immunic by 7.5% during the 3rd quarter. State Street Corp now owns 167,145 shares of the company’s stock valued at $276,000 after acquiring an additional 11,642 shares during the period. Connor Clark & Lunn Investment Management Ltd. boosted its holdings in shares of Immunic by 70.8% in the 3rd quarter. Connor Clark & Lunn Investment Management Ltd. now owns 102,257 shares of the company’s stock valued at $169,000 after acquiring an additional 42,383 shares during the last quarter. Finally, Virtu Financial LLC acquired a new stake in shares of Immunic in the third quarter worth $50,000. 51.82% of the stock is owned by institutional investors and hedge funds.

About Immunic

Immunic, Inc, a biotechnology company, develops a pipeline of selective oral immunology therapies for the treatment of chronic inflammatory and autoimmune diseases in the United States and Germany. Its lead development program is IMU-838, which is in Phase 3 clinical trial, for treatment of multiple sclerosis, including relapsing and progressive multiple sclerosis; and moderate-to-severe ulcerative colitis.